Siemens Share Price Under Pressure from Healthineers Spin-Off Strategy

Siemens shares drop 15% YTD as a planned partial spin-off of Siemens Healthineers overshadows robust Q1 FY2026 order growth of 10% to €21.4B.

Despite posting robust operational figures, Siemens is facing a wave of investor skepticism in the stock market. The industrial conglomerate's shares are trending downward, a reaction primarily driven by a major strategic shift intended to accelerate the company's ongoing transformation, even as its order books remain full.

Strong Fundamentals Meet Market Caution

For the first quarter of fiscal year 2026, Siemens reported a substantial 10% increase in orders, reaching €21.4 billion. The Smart Infrastructure segment was a standout performer, setting a new record with €1.8 billion in data center orders alone amid soaring demand. Revenue also saw a broad-based and noticeable uptick across the company's operations.

This operational strength, however, has failed to translate into positive momentum for the equity. Closing at €202.85 on Friday, the stock has declined 15.79% since the start of the year. The share price now trades significantly below its 200-day moving average, a technical indicator that underscores the persistent phase of weakness.

Strategic Restructuring Weighs on Sentiment

The core source of the downward pressure is Siemens' planned partial spin-off of its medical technology unit, Siemens Healthineers. Management intends to distribute 30% of Healthineers shares directly to existing Siemens shareholders. This move would reduce the parent company's long-term stake from approximately 67% to under 20%. The strategic rationale is to create a more agile Siemens, with a sharpened focus on its core industrial, digitalization, and artificial intelligence businesses.

While market observers generally view this deconsolidation as a sensible long-term decision, the complexity of the transaction is causing short-term hesitation among institutional investors.

Share Buyback and Dividend Pledge Offer Support

To bolster confidence during this transitional period, Siemens is highlighting its ongoing €6 billion share repurchase program. Furthermore, the executive board has guaranteed that the company's progressive dividend policy will remain intact following the Healthineers separation.

The market awaits specific details on the process, which are expected early in the second quarter of 2026. At that time, Siemens plans to clarify outstanding questions regarding tax implications, refinancing, and the precise timeline for the independence of Healthineers. This communication is aimed at alleviating current market uncertainty surrounding the transaction's structure.